BRIU

Briu Biosciences is a clinical-stage biotechnology company focused on developing innovative therapies for autoimmune and inflammatory diseases. The company leverages its expertise in immunology to target key pathways involved in chronic inflammation, such as the IL-17 and JAK/STAT signaling cascades. Briu's lead programs include small molecule inhibitors and monoclonal antibodies designed to provide superior efficacy and safety profiles compared to existing treatments. With a robust pipeline targeting high-prevalence conditions like psoriasis and atopic dermatitis, Briu aims to address significant unmet medical needs in the global immunology market.